ArticleInvestigative ophthalmology & visual science2025
Extracellular Matrix Stiffness Regulates Cancer Stemness in Uveal Melanoma via the PIEZO1-DOT1L Axis.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The symbiotic axis between the acidic tumor microenvironment and cancer stem cells: a driver of malignancy and therapeutic resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cancer stemness drives aggressive behavior and treatment resistance in uveal melanoma (UM). This study aimed to investigate how mechanical signals from the extracellular matrix (ECM) regulated UM stemness through the piezo-type mechanosensitive ion channel component 1 (PIEZO1)-disruptor of telomeric silencing 1-like (DOT1L) signaling axis. Methods: PIEZO1 expression was assessed using immunofluorescence in human UM and adjacent normal tissues. Polyacrylamide hydrogel models with tunable stiffness were used to simulate the biomechanical microenvironment in vitro. Stemness was assessed by analyzing colony formation, tumorsphere assays, apoptosis resistance, and expression of the stemness markers NANOG and SOX2. In vivo, ECM stiffness was reduced to examine its effects on UM progression and stemness. The roles of PIEZO1 and DOT1L in ECM stiffness-mediated regulation of stemness were examined both via short-hairpin RNA (shRNA), lentiviral overexpression, and a PIEZO1 agonist. Results: PIEZO1 was upregulated in UM tissues. In vitro, increased ECM stiffness enhanced UM stemness through PIEZO1. Functioning as a mechanosensor, PIEZO1 promoted DOT1L expression, which consequently upregulated the stemness markers. In vivo, reduced ECM stiffness suppressed tumor growth and downregulated the PIEZO1-DOT1L axis and stemness markers. Inhibition of PIEZO1 or DOT1L diminished stemness properties and tumor growth both in vitro and in vivo. Conclusions: The PIEZO1-DOT1L axis mediated ECM stiffness-driven stemness and tumor progression in UM. Targeting this mechanotransduction pathway by modulating ECM stiffness or its downstream effectors may provide a novel therapeutic strategy for UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.